• Home
  • About Us
    • Board of Directors
    • Advisory Board
    • Our Team
  • Our Science
    • Ionic Liquid Platform
    • Clinical Pipeline
  • Career
  • More
    • Clinical Trials
    • Press Releases
    • In the News
    • Publications
  • Contact Us
  • More
    • Home
    • About Us
      • Board of Directors
      • Advisory Board
      • Our Team
    • Our Science
      • Ionic Liquid Platform
      • Clinical Pipeline
    • Career
    • More
      • Clinical Trials
      • Press Releases
      • In the News
      • Publications
    • Contact Us
  • Home
  • About Us
    • Board of Directors
    • Advisory Board
    • Our Team
  • Our Science
    • Ionic Liquid Platform
    • Clinical Pipeline
  • Career
  • More
    • Clinical Trials
    • Press Releases
    • In the News
    • Publications
  • Contact Us
Closeup of charged molecule segment

What is an Ionic Liquid?

An ionic liquid (IL) is a liquid salt in which the ions are poorly coordinated by association only with ionic bonds and no covalent bonds.  As a result, these solvents remain liquid at or below room temperature and have excellent solvation properties with very low vapor pressure.

How does it work?

Ionic Liquid Platform uses structural heterogeneity of cations & anions to enhance membrane permeation.

capsule image

Delivers wide range of drug APIs including small molecules, peptides, proteins and nucleic acids across the stratum corneum following topical administration, with minimal impact on barrier function.

electrical charges

Enables choice of cations and anions to engineer diverse ILs with 

tailor‐made properties for multiple therapeutic areas. 

Pathogen

Extensive anti-microbial properties. 

Skin Layers

BEST-IN-CLASS platform for immuno-dermatological diseases

CAGE Bio has accumulated a vast amount of in vitro and in vivo evidence supporting the role of ionic liquids in improving tissue-specific delivery of therapeutic entities into the skin.

Learn more
Comparing Ionic Liquid vs. common Skin Penetration Enhancers

Learn the science behind ionic liquids


Copyright © 2020 CAGE Bio Inc. - All Rights Reserved.

  • Board of Directors
  • Our Team
  • Career
  • Contact Us

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept

Welcome! Check out our latest news.

 CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis

Learn more